Full Press Release Details
Tiziana Life Sciences
Announces Purchase of Common Shares by Executive Chairman
New York, September 16, 2022 -
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough
immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an entity
in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 29,318 common shares priced between $0.78 and $0.81
The acquisition takes Mr Cerrone's interests
from 37.70% to 37.72%.
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company
developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana's
innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety
and tolerability compared to intravenous (IV) delivery. Tiziana's two lead candidates, intranasal foralumab, the only fully human
anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients
in studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending
and is expected to allow for broad pipeline applications.
For further inquiries:
Tiziana Life Sciences Ltd
Hana Malik, Business Development, and Investor
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
LifeSci Advisors, LLC